MNOVMEDICINOVA INC

Nasdaq medicinova.com


$ 2.03 $ 0.30 (16.67 %)    

Friday, 06-Sep-2024 15:52:14 EDT
QQQ $ 446.25 $ -12.35 (-2.68 %)
DIA $ 404.28 $ -3.99 (-0.98 %)
SPY $ 539.90 $ -9.25 (-1.68 %)
TLT $ 99.49 $ -0.01 (-0.01 %)
GLD $ 230.65 $ -1.72 (-0.74 %)
$ 2.1
$ 1.98 x 100
-- x --
-- - --
$ 1.12 - $ 2.38
165,694
na
103M
$ 1.35
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 02-15-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-09-2023 06-30-2023 10-Q
6 05-11-2023 03-31-2023 10-Q
7 02-16-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-11-2022 06-30-2022 10-Q
10 05-12-2022 03-31-2022 10-Q
11 02-16-2022 12-31-2021 10-K
12 11-12-2021 09-30-2021 10-Q
13 08-12-2021 06-30-2021 10-Q
14 05-13-2021 03-31-2021 10-Q
15 02-19-2021 12-31-2020 10-K
16 10-26-2020 09-30-2020 10-Q
17 07-28-2020 06-30-2020 10-Q
18 04-23-2020 03-31-2020 10-Q
19 02-13-2020 12-31-2019 10-K
20 10-25-2019 09-30-2019 10-Q
21 07-25-2019 06-30-2019 10-Q
22 04-25-2019 03-31-2019 10-Q
23 02-13-2019 12-31-2018 10-K
24 10-25-2018 09-30-2018 10-Q
25 07-23-2018 06-30-2018 10-Q
26 04-25-2018 03-31-2018 10-Q
27 02-13-2018 12-31-2017 10-K
28 10-23-2017 09-30-2017 10-Q
29 07-26-2017 06-30-2017 10-Q
30 04-26-2017 03-31-2017 10-Q
31 02-14-2017 12-31-2016 10-K
32 10-25-2016 09-30-2016 10-Q
33 07-26-2016 06-30-2016 10-Q
34 04-27-2016 03-31-2016 10-Q
35 02-25-2016 12-31-2015 10-K
36 10-29-2015 09-30-2015 10-Q
37 07-30-2015 06-30-2015 10-Q
38 05-11-2015 03-31-2015 10-Q
39 03-12-2015 12-31-2014 10-K
40 11-13-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 reported-earlier-medicinova-receives-us-patent-allowance-for-mn-166-ensuring-broad-protection-for-post-covid-treatment-through-2042

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the T...

 medicinova-presents-new-data-and-results-of-phase-1b2a-clinical-trial-of-mn-166-at-asco-meeting

The highlights of presentation are as follows: The primary endpoints were safety and tolerability of MN-166 and TMZ combinatio...

 reported-earlier-medicinova-announces-abstract-regarding-results-of-a-clinical-trial-of-mn-166-in-glioblastoma-accepted-for-presentation-at-the-2024-asco

Abstract Number: 2106 Title:  Phase 1b/2a study evaluating the combination of MN-166 (ibudilast) and temozolomide in patients ...

 why-mariadb-shares-are-trading-higher-by-around-100-here-are-20-stocks-moving-premarket

Shares of MariaDB plc (NYSE: MRDB) rose sharply in today’s pre-market trading after Progress Software (NASDAQ: PRGS) announce...

 reported-earlier-medicinova-receives-notice-of-allowance-from-japan-patent-office-for-mn-166-in-macular-injury-treatment

Once issued, this patent is expected to expire no earlier than October 2039.  The allowed claims cover the use of MN-166 (ibudi...

 reported-earlier-medicinova-announces-two-abstracts-regarding-mn-001-and-mn-002-accepted-for-presentation-at-the-92nd-eas-2024-congress

 MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION